Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma-Reference-Cited by-同舟云学术

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

Published:2019-03 Issue: Volume:109 Page:61-69
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Robert Caroline,Flaherty Keith,Nathan Paul,Hersey Peter,Garbe Claus,Milhem Mohammed,Demidov Lev,Mohr Peter,Hassel Jessica C.^ORCID,Rutkowski Piotr,Dummer Reinhard,Utikal Jochen,Kiecker Felix,Larkin James,D'Amelio Anthony,Mookerjee Bijoyesh,Schadendorf Dirk^ORCID

Funder

GSK

Novartis

Roche

Pierre Fabre

Merck

Amgen

BMS

MSD

Philogen

BIOCAD

Leo Pharma

Achilles Therapeutics

Nektar

Pfizer

Genentech

Covance

Immunocore

AstraZeneca

Boston Biomedical

Eisai

EUSA Pharma

Ipsen

Imugene

Incyte

iOnctura

Kymab

Merck Serono

Secarna

Vitaccess

Aveo

Pharmacyclics

Boehringer Ingelheim

4SC

Array

Regeneron

Merck-EMD

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol,2016

2. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial;Ascierto;JAMA Oncol,2018

3. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

4. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study;Long;Ann Oncol,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. Advances in Personalized Oncology;Cancers;2024-08-16

3. Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches;Clinical & Experimental Metastasis;2024-06-27

4. Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study;Cancers;2024-06-11

5. The evolving landscape of tissue‐agnostic therapies in precision oncology;CA: A Cancer Journal for Clinicians;2024-05-30